Etoposide
Etoposide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Autologous Stem Cell Transplant、Classic Hodgkin Lymphoma、Non-Hodgkin Lymphoma、Burkitt Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
0 项
已进入 III/IV 期
14 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Masonic Cancer Center, University of Minnesota
- New York Medical College
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- Boehringer Ingelheim
- Guangzhou Institute of Respiratory Disease
- Yang Li
- Blokhin's Russian Cancer Research Center
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、Russia、澳大利亚、Brazil、Czechia、丹麦、法国、德国、Hungary、意大利、Poland
正在招募患者的 Etoposide 研究
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
II 期招募中美国NCT02605421Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
II 期招募中中国NCT06497530Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
II 期招募中中国NCT06088030Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
I 期招募中美国NCT04301076Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline
II 期招募中RussiaNCT07847190High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
II 期招募中RussiaNCT06418789Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
II 期招募中美国NCT05068232A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
II 期招募中中国NCT07373964A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
I 期 / II 期招募中美国澳大利亚Brazil中国NCT05533775Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
I 期 / II 期招募中美国NCT06110572Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
II 期招募中美国NCT06865339Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
I 期 / II 期招募中中国NCT04432714Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
II 期招募中中国NCT06311981A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
II 期招募中美国NCT07459634CAV Regimen for R/R AML
II 期招募中中国NCT05657639A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
II 期招募中中国NCT07559786SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
I 期 / II 期招募中中国NCT07153068Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
II 期招募中中国NCT06221683Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
II 期招募中美国NCT03418038Follow-up After Surgery for Testicular Cancer
不适用招募中荷兰NCT05670938Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
II 期招募中德国NCT06223711Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
II 期招募中中国NCT06314334Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
II 期招募中美国NCT04803201Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
II 期招募中中国NCT06091124
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。